Abstract 3328: Novel regulation of HER2 degradation and breast cancer cell proliferation by junctional adhesion molecule-a (JAM-A)

• Published in: Cancer research (Chicago, Ill.) Ill.), 2014-10, Vol.74 (19_Supplement), p.3328-3328
• Main Authors: Brennan, Kieran, McSherry, Elaine A., Hudson, Lance, Kay, Elaine W., Young, Leonie S., Hill, Arnold DK, Hopkins, Ann M.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2014-3328

Background: We have previously shown that the adhesion protein Junctional Adhesion Molecule-A (JAM-A) is over-expressed in a population of aggressive and metastatic breast tumours, and that it regulates the migration of breast cells. JAM-dependent regulation of migration could contribute to the likelihood of metastatic disease, since migration is an early event in metastasis. Our objective was to further interrogate the links between JAM-A signalling and markers of disease progression in breast cancer. Approach and Results: Immunohistochemical analysis of JAM-A in two breast cancer tissue microarrays (TMA) revealed that high JAM-A expression correlated significantly with HER2 protein expression, ERnegativity, high grade breast cancers and aggressive luminal B, HER2 and basal subtypes of breast cancer. Using LCC1 and MCF7-HER2 cells which co-express high levels of JAM-A and HER2, we silenced the gene expression of each one in order to examine potential consequences for protein expression of the other. Knockdown of HER2 had no effect on JAM-A protein levels, but knockdown of JAM-A significantly reduced the protein expression of HER2 and its downstream pro-survival effector pAkt. Accordingly, JAM-A knockdown increased apoptosis via a pathway involving Akt activation, as evidenced by apoptosis normalisation upon pharmacological inhibition of Akt. The expressional regulation of HER2 and pAkt by JAM-A was sensitive to inhibition by the proteasomal inhibitor MG132, suggesting that JAM-A regulates the proteasomal degradation of HER2. Finally, over-expression of wild-type JAM-A was sufficient to significantly enhance proliferative and migratory behaviour in breast cell lines. Conclusions: Our results are consistent with a model whereby JAM-A expression inhibits the proteasomal degradation of HER2, facilitating a pro-survival phenotype through increased Akt activity. Therefore JAM-A antagonists may have future therapeutic value in the treatment of breast tumours overexpressing HER2. Citation Format: Kieran Brennan, Elaine A. McSherry, Lance Hudson, Elaine W. Kay, Leonie S. Young, Arnold DK Hill, Ann M. Hopkins. Novel regulation of HER2 degradation and breast cancer cell proliferation by junctional adhesion molecule-a (JAM-A). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3328. doi:10.1158/1538-7445.AM2014-3328